enteroviru
member
enteroviru
genu
picornavirida
famili
frequent
detect
pathogen
handfootandmouth
diseas
hfmd
patient
complic
neurolog
dysfunct
first
isol
california
associ
hfmd
verifi
later
confirm
caus
agent
respons
hfmd
outbreak
hungari
australia
hong
kong
taiwan
japan
singapor
moreov
larg
outbreak
occur
mainland
china
children
year
age
found
particularli
suscept
severest
form
neurolog
diseas
import
public
health
problem
caus
seriou
clinic
ill
potenti
death
young
children
possess
singlestrand
rna
genom
approxim
nucleotid
consist
singl
open
read
frame
orf
flank
untransl
region
utr
untransl
region
utr
orf
express
larg
polyprotein
cleav
region
region
encod
four
structur
protein
region
encod
nonstructur
protein
proteas
respons
viru
replic
virul
proteas
autocatalyt
cleav
nterminu
liber
nascent
polyprotein
proteas
cleav
precursor
three
structur
protein
spontan
assembl
form
crystallin
viruslik
particl
though
signific
increas
epidem
activ
throughout
asiapacif
region
effect
antivir
therapi
vaccin
todat
avail
develop
effect
vaccin
top
prioriti
term
control
strategi
overview
field
vaccin
prepar
date
background
enteroviru
member
enteroviru
genu
picornavirida
famili
one
caus
pathogen
handfootandmouth
diseas
hfmd
common
etiolog
agent
isol
hfmd
patient
complic
neurolog
disord
becom
increasingli
import
neurotrop
enteroviru
postpoliomyel
erad
era
effect
antivir
agent
vaccin
viru
current
still
develop
review
public
develop
vaccin
order
provid
overview
field
method
fiftyf
articl
vaccin
develop
publish
collect
sun
yatsen
univers
librari
review
result
variou
type
vaccin
develop
result
publish
date
vaccin
develop
appear
elicit
immun
respons
rodent
monkey
accord
establish
regulatori
standard
may
rel
easi
acquir
licens
use
inactiv
viru
order
meet
immedi
demand
control
regard
attenu
vaccin
critic
increas
genet
stabil
clinic
use
due
risk
virul
revert
viruslik
particl
vlp
vaccin
conserv
conform
epitop
also
risk
virul
revert
anoth
promis
vaccin
candid
need
develop
capsid
protein
backbon
antigen
protein
develop
subunit
vaccin
epitop
vaccin
remain
viabl
potenti
vaccin
strategi
worthi
studi
develop
conclus
conserv
threedimension
structur
import
inactiv
vaccin
vlp
vaccin
induc
strong
immun
respons
develop
vaccin
high
protect
efficaci
strategi
use
adjuv
strong
promot
tissuespecif
promot
addit
mucos
immun
adjuv
consid
intern
societi
infecti
diseas
publish
elsevi
ltd
right
reserv
convent
vaccin
inactiv
viru
vaccin
inactiv
influenza
vaccin
inactiv
hepat
vaccin
success
use
human
seroepidemiolog
studi
indic
preexist
neutral
antibodi
protect
sever
outcom
infect
yu
et
al
wu
et
al
show
passiv
transfer
serum
formalininactiv
heatinactiv
viru
vaccin
immun
adult
mice
could
provid
protect
challeng
neonat
mice
meanwhil
matern
immun
inactiv
vaccin
abl
prolong
surviv
suckl
mice
lethal
challeng
result
show
valu
inactiv
viru
vaccin
effect
control
howev
conserv
threedimension
structur
import
order
induc
strong
immun
respons
therefor
heatinactiv
viru
much
higher
dose
viral
antigen
adjuv
requir
achiev
accept
level
immunogen
protect
obvious
ideal
vaccin
strain
requir
largescal
prepar
inactiv
vaccin
case
sabin
oral
polio
vaccin
opv
strain
lin
et
al
develop
strain
exhibit
rapid
growth
rate
vero
cell
larger
plaqu
size
lower
lethal
dose
ld
newborn
mice
lin
cowork
show
mous
antiserum
rais
abl
neutral
broad
rang
strain
isol
patient
varieti
geograph
origin
differ
point
time
possess
desir
featur
high
viral
yield
abil
propag
serumfre
medium
strong
immunogen
well
broadbas
antigen
coverag
passag
stabil
indic
potenti
develop
inactiv
vaccin
strain
power
cell
system
also
import
develop
inactiv
vaccin
shown
wu
cowork
serumfre
vero
cell
cultur
gl
cytodex
microcarri
concentr
bioreactor
also
establish
yield
high
titer
tcid
ml
product
basi
studi
wu
et
al
liu
et
al
show
serumfre
cultur
increas
postinfect
cell
death
reduc
viru
product
elicit
higher
neutral
antibodi
titer
immun
mice
compar
serumcontain
cultur
therefor
serumfre
microcarri
cultur
valuabl
techniqu
develop
inactiv
vaccin
larg
scale
exampl
success
attenu
strain
vaccin
sabin
opv
introduc
earli
due
easier
administr
lower
cost
higher
intestin
muscos
immun
inactiv
polio
vaccin
ipv
sinc
approv
worldwid
applic
polioviru
erad
similar
polioviru
arita
et
al
develop
attenu
strain
carri
mutat
utr
polymeras
pol
utr
nontransl
base
attenu
determin
polioviru
strain
character
attenu
neurovirul
limit
spread
viru
subsequ
studi
arita
et
al
three
cynomolgu
monkey
inocul
follow
lethal
challeng
parent
virul
strain
brcrtr
suffer
mild
neurolog
symptom
tremor
surviv
lethal
challeng
without
exacerb
symptom
moreov
sera
immun
monkey
show
broad
spectrum
neutral
activ
differ
genotyp
find
indic
act
effect
antigen
howev
caus
mild
neurolog
symptom
inocul
via
intraven
rout
addit
studi
requir
ensur
attenu
produc
effect
attenu
vaccin
strain
infect
via
oral
rout
effici
caus
neurolog
disord
inocul
monkey
therefor
cynomolgu
monkey
inocul
intraven
rout
instead
oral
rout
evalu
antigen
attenu
vaccin
thu
develop
oral
attenu
vaccin
valid
anim
model
infect
oral
rout
urgent
need
meanwhil
well
known
small
number
opv
recipi
close
contact
especi
primari
humor
immunodefici
vaccin
strain
mutat
neurovirul
strain
opv
replic
caus
vaccineassoci
paralyt
poliomyel
vapp
advers
side
effect
opv
world
health
organ
collabor
studi
found
vapp
rate
one
everi
million
dose
administ
vaccin
recipi
one
everi
million
dose
administ
contact
therefor
genet
stabil
attenu
opv
major
concern
effort
made
attenu
neurotox
effect
increas
genet
stabil
attenu
vaccin
clinic
use
overcom
potenti
problem
revers
virul
attenu
strain
vaccin
subunit
vaccin
consist
one
subunit
protein
pathogen
stimul
immun
respons
direct
intact
viru
develop
use
recombin
dna
technolog
common
enterovirus
respons
antigen
divers
enterovirus
major
capsid
protein
cluster
neutral
epitop
potenti
act
antivir
subunit
vaccin
wu
et
al
describ
recombin
protein
express
escherichia
coli
show
protein
complet
adjuv
abl
elicit
neutral
antibodi
respons
enhanc
helper
cell
prolifer
induc
high
level
interleukin
il
interferon
ifn
g
mice
provid
direct
evid
protein
contain
neutral
epitop
independ
viral
capsid
protein
pave
way
use
backbon
antigen
develop
subunit
vaccin
transgen
edibl
plant
mammalian
gland
possibl
altern
prokaryot
eukaryot
cell
cultur
system
offer
palat
oral
deliveri
system
elicit
good
mucos
immun
respons
well
system
humor
cellular
immun
respons
make
particularli
suitabl
protect
infecti
agent
intrud
via
mucos
surfac
initi
diseas
follow
implant
gut
mucosa
show
potenti
oral
vaccin
immun
infect
chen
colleagu
develop
transgen
tomato
fruit
use
mous
freefeed
oral
vaccin
fecal
iga
serum
igg
observ
mice
humor
cellular
immun
establish
show
potenti
use
transgen
tomato
oral
vaccin
meanwhil
oral
vaccin
deliveri
system
milk
transgen
mice
describ
chen
et
al
salmonellabas
method
chiu
et
al
extens
explor
oral
vaccin
gastric
acid
enzymat
digest
major
concern
sinc
may
interfer
vaccin
absorpt
enteroviru
genu
withstand
human
gastric
acid
remain
infecti
ph
howev
capsid
protein
surfac
particl
whether
resist
human
gastric
acid
fulli
address
meanwhil
digest
enzym
may
also
degrad
antigen
experi
chen
et
al
mice
gavag
protein
produc
antibodi
mice
fed
transgen
tomato
contain
protein
sera
fece
indic
chew
digest
caus
degrad
antigen
also
oral
rotaviru
protein
vaccin
shown
provid
lower
level
antibodi
less
protect
immun
inject
rotaviru
protein
indic
possibl
interfer
digest
enzym
moreov
difficult
determin
precis
dose
antigen
immun
sinc
competit
food
microbi
antigen
interfer
absorpt
rate
vaccin
compon
therefor
improv
oral
vaccin
deliveri
mani
strategi
develop
use
tissuespecif
promot
addit
mucos
immun
adjuv
use
liposom
protect
fusion
peptid
phospholipid
bilay
vesicl
gastric
enzym
ntrimethyl
chitosan
nanoparticl
oral
subunit
vaccin
explor
strategi
protect
antigen
enzym
degrad
gut
necessari
dna
vaccin
express
intracellularli
manner
natur
viral
infect
stimul
either
humor
immun
cellular
immun
also
dna
vaccin
deliv
target
subunit
antigen
thu
caus
fewer
advers
effect
make
anoth
valuabl
vaccin
choic
viral
infect
tung
cowork
develop
dna
vaccin
insert
gene
eukaryot
express
vector
evalu
immun
respons
mice
studi
result
show
igg
level
increas
mice
immun
dna
vaccin
contrast
level
declin
boost
immun
furthermor
although
igg
exhibit
neutral
activ
neutral
effect
sera
mice
immun
dna
vaccin
much
lower
human
serum
anoth
dna
vaccin
develop
wu
et
al
elicit
high
neutral
titer
stabl
titer
level
could
detect
even
late
postimmun
time
howev
dna
vaccin
contain
fewer
antigen
epitop
induc
weaker
immun
stimul
whole
viru
particl
therefor
strategi
increas
immun
stimul
abil
dna
vaccin
develop
includ
incorpor
immunostimulatori
sequenc
backbon
plasmid
coexpress
stimulatori
molecul
use
localizationsecretori
signal
appropri
deliveri
system
well
adjuv
optim
transgen
express
techniqu
help
prepar
better
dna
vaccin
epitop
peptid
vaccin
consist
welldefin
immunogen
epitop
stimul
effect
specif
protect
immun
respons
avoid
potenti
undesir
effect
host
immun
respons
develop
upon
viral
infect
primarili
celldepend
includ
induct
cytotox
cellular
respons
effici
antibodi
respons
thu
identif
cell
epitop
b
cell
epitop
great
import
design
effect
epitop
peptid
vaccin
foo
colleagu
publish
sever
studi
aim
identifi
tcell
bcell
epitop
studi
identifi
three
region
span
amino
acid
protein
show
three
region
could
induc
prolifer
cell
produc
abund
ifng
upon
stimul
addit
among
three
peptid
amino
acid
induc
strongest
prolif
respons
highest
cytokin
product
furthermor
order
identifi
neutral
linear
epitop
overlap
synthet
peptid
span
capsid
protein
use
immun
mice
peptid
contain
amino
acid
protein
capabl
elicit
neutral
antibodi
neutral
antibodi
elicit
synthet
peptid
abl
confer
good
vivo
passiv
protect
homolog
heterolog
strain
suckl
balbc
mice
moreov
monoclon
antibodi
gener
immun
mice
amino
acid
show
strong
neutral
activ
vitro
neutral
assay
therefor
epitop
peptid
vaccin
repres
promis
candid
identif
tcell
bcell
epitop
protein
well
combin
epitop
peptid
vaccin
consid
search
effect
epitop
peptid
vaccin
vlp
empti
particl
compos
major
structur
protein
mimick
organ
conform
nativ
particl
date
shown
wide
rang
vlp
clinic
import
virus
eg
hiv
sever
acut
respiratori
syndrom
coronaviru
induc
effect
neutral
antibodi
cytotox
cell
respons
vlp
vaccin
conserv
conform
epitop
also
risk
virul
revert
also
promis
vaccin
strategi
hu
et
al
chung
et
al
use
recombin
baculoviru
express
system
express
protein
protein
cleav
precursor
spontan
assembl
form
vlp
induc
immun
respons
importantli
vlp
immun
mother
mice
confer
protect
neonat
mice
lethal
viral
challeng
indic
vlp
promis
vaccin
chung
et
al
also
found
compar
intact
vlp
denatur
vlp
elicit
significantli
lower
level
neutral
antibodi
confer
lower
degre
protect
viru
challeng
highlight
import
preserv
conformationdepend
epitop
prevent
infect
present
vlp
mostli
develop
use
insect
cell
strict
cultur
condit
limit
requir
larg
scale
vaccin
product
thu
transgen
plant
yeast
produc
vlp
deliv
either
oral
administr
inject
might
promis
express
system
one
caus
pathogen
hfmd
often
complic
neurolog
disord
due
similar
polioviru
mani
virolog
clinic
aspect
success
oral
polio
vaccin
inactivatedviru
prepar
control
poliomyel
erad
polioviru
highlight
potenti
control
vaccin
polioviru
vaccin
technolog
live
attenu
inactiv
viru
vaccin
adapt
control
infect
recent
year
variou
type
vaccin
develop
yet
remain
preclin
stage
outbreak
report
around
world
sinc
econom
develop
nation
typic
caus
mild
ill
patient
usual
recov
quickli
howev
sinc
late
signific
increas
epidem
emerg
seriou
threat
public
health
throughout
asiapacif
region
develop
countri
resourc
vaccin
research
develop
view
prioriti
vaccin
industri
develop
countri
littl
incent
develop
vaccin
present
vaccin
industri
asiapacif
region
undertak
vaccin
prepar
therefor
effect
control
effort
cooper
worldwid
need
mainli
threaten
children
develop
countri
ideal
vaccin
would
inexpens
safe
conveni
administ
accept
parent
inactiv
viru
vaccin
establish
regulatori
standard
may
allow
licens
obtain
meet
immedi
demand
control
due
need
conserv
threedimension
structur
formalininactiv
viru
vaccin
potenti
candid
vaccin
oral
attenu
vaccin
potenti
control
way
opv
control
polioviru
though
attenu
procedur
need
present
five
genotyp
crossprotect
differ
genotyp
vaccin
current
develop
unclear
henc
prepar
vaccin
strain
provid
wide
crossprotect
anoth
import
issu
vaccin
develop
conflict
interest
regard
employ
consult
stock
ownership
honoraria
paid
expert
testimoni
patent
applicationsregistr
grant
declar
fund
sourc
